GLP-3 (50mg)

Recent research & studies

• Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. — PubMed • Ding M et al. • iScience • 2026 Sep 18

  Chronic kidney disease is a major health burden. Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy, we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO…

• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — ClinicalTrials.gov • Active Not Recruiting • Phase3 • August 24, 2026

  The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher…

• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight — ClinicalTrials.gov • Completed • Phase3 • August 21, 2026

  The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea…

• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) — ClinicalTrials.gov • Recruiting • Phase3 • August 21, 2026

  The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD…

• GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation. — PubMed • Schifano F et al. • Curr Psychiatry Rep • 2026 Aug 21

  Purpose Of Review: This review evaluates evidence linking both GLP-1 and GIP/GLP-1RAs' exposure to a range of neuropsychiatric outcomes using the Bradford Hill criteria for causal inference. Recent Findings: Glucagon-like peptide-1 (GLP-1) and the dual glucose-dependent insulinotropic polypeptide-GIP/GLP-1 receptor agonists…

• Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. — PubMed • Ruotolo G et al. • Diabetes Obes Metab • 2026 Aug 17

  Aims: To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). Materials And Methods: Data were analysed…

These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.